Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Opening Session Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Apr

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Opening Session Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Melanoma Can AI Enable Diagnosis Prediction

AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers

DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors

Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC

Romiplostim for Chemotherapy-Induced Thrombocytopenia